$INZY News

Last published 1y ago

1y agoBMRN INZYBioMarin Announces Completion of Acquisition of InozymePR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq:...
1y agoINZYInozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of StockholdersGlobeNewswireBOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the "Annual Meeting"), which was scheduled to be held on June
1y agoBMRN INZYBioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme PharmaPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Inozyme Pharma, Inc. (Nasdaq: INZY) announced today that BioMarin has entered into a definitive...
1y agoINZYInozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business HighlightsGlobeNewswire- Interim data from ENERGY 3 trial highlight INZ-701's potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date - - ENERGY 3
1y agoINZYInozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 DeficiencyGlobeNewswire- Data from the largest retrospective analysis of ENPP1 Deficiency provides insights into the evolution of the disease's serious cardiovascular and musculoskeletal complications - - Findings highlight the urgent need
1y agoINZYInozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireBOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect
1y agoINZYInozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business HighlightsGlobeNewswire- Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including an approximately 25% workforce reduction, expected to
1y agoINZYInozyme Pharma to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewswireBOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect
1y agoINZYInozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025GlobeNewswireBOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect
1y agoINZYInozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program UpdatesGlobeNewswire- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including survival, heart function, and stabilization or reduction in
1y agoINZYInozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswireBOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect
2y agoINZYInozyme Pharma to Present at Upcoming Investor ConferencesGlobeNewswireBOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect
2y agoINZYInozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business HighlightsGlobeNewswire- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1
2y agoINZYInozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701GlobeNewswire- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with calciphylaxis, a
2y agoINZYInozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024GlobeNewswireBOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect
2y agoINZYInozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of DirectorsGlobeNewswireBOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect
2y agoINZYInozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual MeetingGlobeNewswire- Data underscore the urgent need for therapies that address the cardiovascular and musculoskeletal complications and long-term systemic effects of ENPP1 and ABCC6 Deficiencies in children - - Inozyme and GACI Global
2y agoINZYInozyme Pharma to Participate at the 2024 Wells Fargo Healthcare ConferenceGlobeNewswireBOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect
2y agoINZYInozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business HighlightsGlobeNewswire- Complete enrollment in ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected third quarter of 2024 - - Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1
2y agoINZYInozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel FunctionGlobeNewswire- Treatment with INZ-701 shown to prevent intimal proliferation in both ENPP1-deficient and wild-type mice, supporting its potential therapeutic application beyond traditional ERT - BOSTON, July 25, 2024 (GLOBE
2y agoINZYInozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 DeficiencyGlobeNewswireBOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
2y agoINZYInozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children's Bone Health (ICCBH)GlobeNewswireBOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
2y agoINZYInozyme Pharma to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireBOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
2y agoINZYInozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical ConferencesGlobeNewswireBOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
2y agoINZYInozyme Pharma to Participate at the Bank of America Securities 2024 Health Care ConferenceGlobeNewswireBOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
2y agoINZYInozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business HighlightsGlobeNewswire- Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 2024 - - Interim data from ENERGY-1, a Phase 1b trial of INZ-701
2y agoINZYInozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
2y agoINZYInozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 DeficiencyGlobeNewswire- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study highlights stroke as
2y agoINZYInozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
2y agoINZYInozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswireBOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
2y agoINZYInozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024GlobeNewswire- Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET - BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or
2y agoINZYInozyme Pharma Reports Full Year 2023 Financial Results and Provides Business HighlightsGlobeNewswire– Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April – – Phase 1 trial of INZ-701 in end-stage kidney disease (ESKD) patients receiving
2y agoINZYInozyme Pharma to Participate in the TD Cowen 44th Annual Health Care ConferenceGlobeNewswireBOSTON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
2y agoINZYInozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
2y agoINZYInozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
3y agoINZYInozyme Pharma to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
3y agoINZYInozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewswire– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 – – Topline data readouts from ongoing Phase 1/2 trials of INZ-701 in
3y agoINZYInozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY)("Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
3y agoINZYInozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023GlobeNewswireBOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
3y agoINZYInozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England's Generation Study of Rare ConditionsGlobeNewswireBOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
3y agoINZYInozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual MeetingGlobeNewswireBOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
3y agoINZYInozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)GlobeNewswire- Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient reported outcomes (PROs) and functional outcomes - - Improvement in the Global Impression of
3y agoINZYInozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023GlobeNewswireBOSTON, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY)("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
3y agoINZYInozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY)("Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
3y agoINZYInozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireBOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and
3y agoINZYInozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewswire– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 – – Plasma pyrophosphate (PPi) to serve as primary
3y agoINZYInozyme Pharma, Inc. Announces Closing of Public Offering of Common StockGlobeNewswireBOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and
3y agoINZYInozyme Pharma, Inc. Announces Pricing of Public Offering of Common StockGlobeNewswireBOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and
3y agoINZYInozyme Pharma, Inc. Announces Proposed Offering of Common StockGlobeNewswireBOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and
3y agoINZYInozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 DeficiencyGlobeNewswire- Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint in the EU for planned ENERGY-3 pivotal trial in pediatric patients - - ENERGY-3 pivotal trial in pediatric patients expected